Ticker: TSX - TOS
Shares Outstanding: 57,896,123
QUÉBEC CITY, March 16 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings using ozone, announced today that its new generation STERIZONE(R) Sterilization System, is being exhibited in the 3M(TM)booth under the 3M(TM) brand Optreoz(TM)125-Z Sterilizer at the Association of Perioperative Registered Nurses (AORN) 57th Annual Congress held from March 13 to 18 in Denver, Colorado.
AORN's annual Congress (http://www.aorn.org/ExhibitorsAndAdvertisers/AnnualCongress/) is the world's premier educational event and tradeshow addressing the needs for the Operating Room (OR) suite, including sterile reprocessing. Nearly 7,000 perioperative nurses and nurse managers, representing over 2,000 hospitals and facilities, gather each year at this event to keep up-to-date with the latest in recommended practices, hot topics, products, and services. 80% of all Congress attendees have influence over purchasing in their facilities.
"It is a very exciting time for TSO3. Seeing our product presented at AORN in the 3M(TM) booth under the 3M(TM) brand attests to the importance of recent enhancements in both cycle development and distribution strength", said R. M. (Ric) Rumble, CEO at TSO3.
On December 16 2009, TSO3 announced a global channel partnership with 3M(TM) Infection Prevention Division, for the exclusive supply and distribution of its new generation sterilizer through 3M's worldwide operations under the 3M(TM) brand, as regulatory clearances are received.
Also in December 2009, TSO3 filed for regulatory clearances on the new generation product in Canada, Europe and the United States. TSO3 has now received authorizations from both Health Canada and the notification from the European Notified Body (CE Mark), allowing the sale of the product in Canada and in the European Union. The product is not available for sale in the United States. A 510k has been submitted and is currently under review.
The new generation sterilizer offers three sterilization cycles in a single unit and is able to quickly and gently sterilize packaged simple and complex medical devices. These devices range from general surgical instruments, to short and long, rigid and flexible endoscopes, including complex multi-channel devices.
AORN is the global leader in promoting excellence in perioperative nursing practice, supporting registered nurses in achieving optimal outcomes for patients undergoing surgical and other invasive procedures. The Association is composed of approximately 40,000 perioperative registered nurses in the United States and abroad. Perioperative nurses are defined as "those who provide, manage, teach, and study the care of patients undergoing operative or other invasive procedures."
AORN was formally organized between 1949 and 1954. The first national conference was held in 1954. The organization was formally incorporated as AORN, Inc, in 1960. The Headquarters office was relocated to Denver in 1969.
For more information on AORN, visit the association's Web Site at: http://www.aorn.org
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available at http://photos.newswire.ca. Images are free to accredited members of the media/
SOURCE TSO3 Inc.
For further information: For further information: Caroline Côté, Director, Corporate Communications and Investor Relations, (418) 651-0003, Ext. 237, email@example.com; Source: TSO(3) Inc.